Leflunomide inhibits proliferation and tumorigenesis of oral squamous cell carcinoma

Ren,Aishu; Fu,Gang; Qiu,Yu; Cui,Hongjuan

doi:10.3892/mmr.2017.7755

Leflunomide inhibits proliferation and tumorigenesis of oral squamous cell carcinoma

Authors:
- Aishu Ren
- Gang Fu
- Yu Qiu
- Hongjuan Cui
View Affiliations

Affiliations: State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400716, P.R. China, Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Affiliated Hospital of Stomatology, Chongqing Medical University, Chongqing 401147, P.R. China
Published online on: October 10, 2017 https://doi.org/10.3892/mmr.2017.7755
Pages: 9125-9130

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oral squamous cell carcinoma (OSCC) is the most prevalent pathological cancer occurring in the head and neck area. Progress has previously been made regarding treatment strategies of OSCC, however the 5‑year survival rate of these patients is only 50%. The present study examined if leflunomide (LEF), a drug primarily used for the treatment of rheumatoid arthritis, exhibited antitumor effects in OSCC. The results demonstrated that LEF inhibited cell proliferation and blocked the cell cycle at the S phase in OSCC cells, with upregulation of cyclin A protein expression. LEF reduced the expression of dihydroorotate dehydrogenase, which is an essential enzyme in the de novo pyrimidine biosynthetic pathway. LEF additionally inhibited colony formation in soft agar and reduced tumor growth in a xenograft model. The results suggested that LEF may act as a potential therapeutic agent in the treatment of OSCC in the future.

View Figures

View References

1	Argiris A, Karamouzis MV, Raben D and Ferris RL: Head and neck cancer. Lancet. 371:1695–1709. 2008. View Article : Google Scholar : PubMed/NCBI
2	Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1999. CA Cancer J Clin. 49:8–31. 1999. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
4	Bettendorf O, Piffkò J and Bànkfalvi A: Prognostic and predictive factors in oral squamous cell cancer: Important tools for planning individual therapy? Oral Oncol. 40:110–119. 2004. View Article : Google Scholar : PubMed/NCBI
5	Teschner S and Burst V: Leflunomide: A drug with a potential beyond rheumatology. Immunotherapy. 2:637–650. 2010. View Article : Google Scholar : PubMed/NCBI
6	Pinto P and Dougados M: Leflunomide in clinical practice. Acta Reumatol Port. 31:215–224. 2006.PubMed/NCBI
7	Xu X, Shen J, Mall JW, Myers JA, Huang W, Blinder L, Saclarides TJ, Williams JW and Chong AS: In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: Mechanisms of action. Biochem Pharmacol. 58:1405–1413. 1999. View Article : Google Scholar : PubMed/NCBI
8	Strawn LM, Kabbinavar F, Schwartz DP, Mann E, Shawver LK, Slamon DJ and Cherrington JM: Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. Clin Cancer Res. 6:2931–2940. 2000.PubMed/NCBI
9	Ringshausen I, Oelsner M, Bogner C, Peschel C and Decker T: The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia. 22:635–638. 2008. View Article : Google Scholar : PubMed/NCBI
10	Dietrich S, Krämer OH, Hahn E, Schäfer C, Giese T, Hess M, Tretter T, Rieger M, Hüllein J, Zenz T, et al: Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells. Clin Cancer Res. 18:417–431. 2012. View Article : Google Scholar : PubMed/NCBI
11	White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl PB, Burke CJ, Langdon E, Tomlinson ML, Mosher J, Kaufman C, et al: DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature. 471:518–522. 2011. View Article : Google Scholar : PubMed/NCBI
12	Zhu S, Yan X, Xiang Z, Ding HF and Cui H: Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo. PLoS One. 8:e715552013. View Article : Google Scholar : PubMed/NCBI
13	Alhefdhi A, Burke JF, Redlich A, Kunnimalaiyaan M and Chen H: Leflunomide suppresses growth in human medullary thyroid cancer cells. J Surg Res. 185:212–216. 2013. View Article : Google Scholar : PubMed/NCBI
14	Greene S, Watanabe K, Braatz-Trulson J and Lou L: Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol. 50:861–867. 1995. View Article : Google Scholar : PubMed/NCBI
15	Bruneau JM, Yea CM, Spinella-Jaegle S, Fudali C, Woodward K, Robson PA, Sautès C, Westwood R, Kuo EA, Williamson RA and Ruuth E: Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J. 336:299–303. 1998. View Article : Google Scholar : PubMed/NCBI
16	Baumann P, Mandl-Weber S, Völkl A, Adam C, Bumeder I, Oduncu F and Schmidmaier R: Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther. 8:366–375. 2009. View Article : Google Scholar : PubMed/NCBI
17	Hail N Jr, Chen P and Bushman LR: Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: Evidence supporting a role for teriflunomide in prostate cancer chemoprevention. Neoplasia. 12:464–475. 2010. View Article : Google Scholar : PubMed/NCBI
18	Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, et al: Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res. 3:1167–1177. 1997.PubMed/NCBI
19	Mattar T, Kochhar K, Bartlett R, Bremer EG and Finnegan A: Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. 334:161–164. 1993. View Article : Google Scholar : PubMed/NCBI
20	Xu X, Williams JW, Gong H, Finnegan A and Chong AS: Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol. 52:527–534. 1996. View Article : Google Scholar : PubMed/NCBI